MDA-MB-468 cell line treated with AKTi (ipatasertib) and EZH2i (tazemetostat)

MDA-MB-468 cell line treated with AKTi (ipatasertib) and EZH2i (tazemetostat). Overall design: On day -5, MDA-MB-468 cells were seeded at 40% confluency and treated with 5uM tazemetostat or DMSO. On day -3, cells were passaged again at 40% confluency and maintained in DMSO or tazemetostat. On day -1, cells were seeded into 6cm plates at 250,000 cells per plate and maintained in DMSO or tazemetostat. On day 0, cells were treated in media containing 2% FBS with AKTi (ipatasertib) and/or EZH2i (tazemetostat). Cells were collected at 24 hours, RNA was isolated and then sequenced using NGS.